DaVita Inc. (NYSE:DVA) Shares Sold by Metis Global Partners LLC

Metis Global Partners LLC reduced its holdings in DaVita Inc. (NYSE:DVA) by 7.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,543 shares of the company’s stock after selling 117 shares during the quarter. Metis Global Partners LLC’s holdings in DaVita were worth $253,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Transcendent Capital Group LLC bought a new position in DaVita in the 3rd quarter valued at about $25,000. Blue Trust Inc. raised its stake in shares of DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after buying an additional 78 shares in the last quarter. Family Firm Inc. bought a new position in DaVita during the second quarter valued at about $43,000. Versant Capital Management Inc raised its position in DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after acquiring an additional 155 shares in the last quarter. Finally, Friedenthal Financial bought a new position in shares of DaVita during the 2nd quarter valued at about $48,000. Institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Bank of America raised their target price on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. Barclays boosted their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. UBS Group increased their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. TD Cowen raised their target price on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Finally, Truist Financial upped their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, DaVita presently has an average rating of “Hold” and a consensus target price of $161.80.

DaVita Stock Performance

DVA stock opened at $156.98 on Wednesday. The firm has a 50 day simple moving average of $157.99 and a 200 day simple moving average of $147.88. DaVita Inc. has a 52 week low of $95.60 and a 52 week high of $168.50. The stock has a market cap of $12.87 billion, a P/E ratio of 16.93, a P/E/G ratio of 0.90 and a beta of 0.89. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. During the same period last year, the business earned $2.85 EPS. The company’s quarterly revenue was up 4.6% on a year-over-year basis. Research analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This trade represents a 5.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Joel Ackerman sold 64,029 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the sale, the chief financial officer now owns 111,481 shares of the company’s stock, valued at $17,286,243.86. This represents a 36.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 156,086 shares of company stock worth $24,807,161 over the last ninety days. 2.00% of the stock is currently owned by insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.